You can buy or sell IDRA and other stocks, options, ETFs, and crypto commission-free!
Idera Pharmaceuticals, Inc. Common Stock, also called Idera Pharmaceuticals, is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. Read More The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Simply Wall StMar 7
Easy Come, Easy Go: How Idera Pharmaceuticals Shareholders Got Unlucky And Saw 94% Of Their Cash Evaporate
Long term investing is the way to go, but that doesn’t mean you should hold every stock forever. We really hate to see fellow investors lose their hard-earned money. Spare a thought for those who held Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for five whole years – as the share price tanked 94%. And we doubt long term believers are the only worried holders, since the stock price has declined 82% over the last twelve months. Shareholders have had an even rougher run lately, with the share price down 54% in t...
Stock Price, News, & Analysis for Idera Pharmaceuticals
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipi...
Expected May 9, After Hours